002020 京新药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.77012.84412.40111.61313.235
总资产报酬率 ROA (%)2.0429.1318.6488.0649.522
投入资产回报率 ROIC (%)2.54711.55710.97510.13011.708

边际利润分析
销售毛利率 (%)51.08350.14949.97450.57353.275
营业利润率 (%)21.03221.19920.28617.85720.017
息税前利润/营业总收入 (%)20.90120.13018.74616.36017.937
净利润/营业总收入 (%)18.00018.84017.29315.59017.668

收益指标分析
经营活动净收益/利润总额(%)96.60397.29193.43989.23292.627
价值变动净收益/利润总额(%)0.8163.075-3.9596.1035.780
营业外收支净额/利润总额(%)-1.4410.1930.044-0.850-0.840

偿债能力分析
流动比率 (X)2.0311.7311.3611.6161.807
速动比率 (X)1.5131.3290.9891.3021.381
资产负债率 (%)23.90127.73729.22130.63129.753
带息债务/全部投入资本 (%)1.3663.9425.5666.4526.879
股东权益/带息债务 (%)6,824.7452,300.4061,604.4891,358.4101,261.677
股东权益/负债合计 (%)316.405258.871240.923225.326234.920
利息保障倍数 (X)124.220-18.139-12.098-12.154-9.375

营运能力分析
应收账款周转天数 (天)73.91567.81157.10547.07944.518
存货周转天数 (天)157.480138.318125.062129.902147.920